NO2718293T3 - - Google Patents

Info

Publication number: NO2718293T3
Authority: NO; Norway

Application number

NO12797167A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-08

Filing date

2012-06-07

Publication date

2018-03-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295336&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2718293(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-07 Application filed filed Critical

2018-03-24 Publication of NO2718293T3 publication Critical patent/NO2718293T3/no

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

NO12797167A 2011-06-08 2012-06-07 NO2718293T3 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/CN2011/075431 WO2012167423A1 (en)	2011-06-08	2011-06-08	Substituted pyridopyrazines as novel syk inhibitors
PCT/CN2012/076576 WO2012167733A1 (en)	2011-06-08	2012-06-07	Substituted pyridopyrazines as novel syk inhibitors

Publications (1)

Publication Number	Publication Date
NO2718293T3 true NO2718293T3 (zh)	2018-03-24

Family

ID=47295336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO12797167A NO2718293T3 (zh)	2011-06-08	2012-06-07

Country Status (31)

Country	Link
US (2)	US9434726B2 (zh)
EP (1)	EP2718293B1 (zh)
JP (2)	JP5940148B2 (zh)
KR (1)	KR101571720B1 (zh)
CN (1)	CN103596952B (zh)
AU (1)	AU2012266941B2 (zh)
BR (1)	BR112013031405B1 (zh)
CA (1)	CA2836227C (zh)
CL (1)	CL2013003512A1 (zh)
CY (1)	CY1119953T1 (zh)
DK (1)	DK2718293T3 (zh)
ES (1)	ES2657549T3 (zh)
HK (1)	HK1190143A1 (zh)
HR (1)	HRP20180139T1 (zh)
HU (1)	HUE037934T2 (zh)
IL (1)	IL229410A (zh)
LT (1)	LT2718293T (zh)
MX (1)	MX355671B (zh)
MY (1)	MY186599A (zh)
NO (1)	NO2718293T3 (zh)
PE (1)	PE20141167A1 (zh)
PL (1)	PL2718293T3 (zh)
PT (1)	PT2718293T (zh)
RS (1)	RS56901B1 (zh)
RU (1)	RU2569635C9 (zh)
SG (1)	SG195035A1 (zh)
SI (1)	SI2718293T1 (zh)
TW (1)	TWI494311B (zh)
UA (1)	UA111744C2 (zh)
WO (2)	WO2012167423A1 (zh)
ZA (1)	ZA201308947B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140005188A1 (en) *	2011-03-11	2014-01-02	Glaxo Group Limited	Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2012167423A1 (en) *	2011-06-08	2012-12-13	Hutchison Medipharma Limited	Substituted pyridopyrazines as novel syk inhibitors
JP6193374B2 (ja)	2012-08-13	2017-09-06	武田薬品工業株式会社	Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体
US20150307491A1 (en) *	2012-12-07	2015-10-29	Hutchison Medipharma Limited	Substituted pyridopyrazines as syk inhibitors
EP3105230B1 (en)	2014-02-14	2021-04-07	Takeda Pharmaceutical Company Limited	Pyridopyrazines modulators of gpr6
CN110183440B (zh)	2014-03-19	2022-04-22	勃林格殷格翰国际有限公司	杂芳基syk抑制剂
KR20180026459A (ko)	2015-06-18	2018-03-12	세파론, 인코포레이티드	1,4-치환된 피페리딘 유도체
ES2849951T3 (es)	2015-06-18	2021-08-24	89Bio Ltd	Derivados de piperidina 4-bencil y 4-benzoil sustituidos
CN105153211B (zh) *	2015-09-22	2017-02-01	上海晋鲁医药科技有限公司	一种合成1‑(N‑Boc‑4‑哌啶)‑4‑吡唑硼酸频哪醇酯的方法
EP3556761B1 (en)	2017-02-08	2021-03-03	The National Institutes Of Pharmaceutical Research	Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
CA3070171A1 (en) *	2017-07-18	2019-01-24	Merck Patent Gmbh	Tlr7/8 antagonists and uses thereof
CN109422741A (zh) *	2017-08-22	2019-03-05	和记黄埔医药（上海）有限公司	化合物的盐及其晶型
KR20210142154A (ko)	2019-03-21	2021-11-24	옹쎄오	암 치료를 위한 키나제 억제제와 조합된 dbait 분자
US20220401436A1 (en)	2019-11-08	2022-12-22	INSERM (Institute National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
TW202313608A (zh) *	2021-06-04	2023-04-01	美商建南德克公司	２，８—二氮雜螺［４．５］癸烷化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4022779A (en) *	1974-07-25	1977-05-10	E. R. Squibb & Sons, Inc.	Amino derivatives of pyrido(3,4-b)pyrazine carboxylic acids and esters
US3989816A (en)	1975-06-19	1976-11-02	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en)	1980-04-04	1984-04-24	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacyclopentan-2-ones
JP2001302667A (ja)	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US20030158195A1 (en)	2001-12-21	2003-08-21	Cywin Charles L.	1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
CA2491680C (en) *	2002-07-02	2012-04-17	Southern Research Institute	Inhibitors of ftsz and uses thereof
DE10323345A1 (de) *	2003-05-23	2004-12-16	Zentaris Gmbh	Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
PT1856135E (pt)	2005-01-19	2010-02-26	Rigel Pharmaceuticals Inc	Pró-fármacos de compostos 2,4-pirimidinodiamina e suas utilizações
US8227455B2 (en)	2005-04-18	2012-07-24	Rigel Pharmaceuticals, Inc.	Methods of treating cell proliferative disorders
RU2515944C9 (ru) *	2005-11-11	2014-07-20	Этерна Центарис ГмбХ	ПРОИЗВОДНЫЕ ПИРИДОПИРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ФИЗИОЛОГИЧЕСКИХ И/ИЛИ ПАТОФИЗИОЛОГИЧЕСКИХ СОСТОЯНИЙ ПОСРЕДСТВОМ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ ERK, ERK1, ERK2, PI3K, PI3Kальфа, PI3Kбета, PI3Kгамма, PI3Kдельта, PI3K-С2альфа, PI3K-С2бета, PI3K-Vps34р (ВАРИАНТЫ)
TW200942537A (en) *	2008-02-01	2009-10-16	Irm Llc	Compounds and compositions as kinase inhibitors
WO2010015520A1 (de)	2008-08-05	2010-02-11	Boehringer Ingelheim International Gmbh	Substituierte naphthyridine und ihre verwendung als arzneimittel
WO2011014795A2 (en)	2009-07-30	2011-02-03	Irm Llc	Compounds and compositions as syk kinase inhibitors
PL2477987T3 (pl) *	2009-09-14	2018-06-29	Gilead Sciences, Inc.	Modulatory receptorów toll-podobnych
EP2528915B1 (en)	2010-01-29	2015-10-28	Boehringer Ingelheim International GmbH	Substituted naphthyridines and their use as syk kinase inhibitors
GB201007203D0 (en)	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
US20140005188A1 (en) *	2011-03-11	2014-01-02	Glaxo Group Limited	Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2012167423A1 (en) *	2011-06-08	2012-12-13	Hutchison Medipharma Limited	Substituted pyridopyrazines as novel syk inhibitors
EP2736886B1 (en)	2011-07-26	2016-09-14	Boehringer Ingelheim International GmbH	Substituted quinolines and their use as medicaments

2011
- 2011-06-08 WO PCT/CN2011/075431 patent/WO2012167423A1/en active Application Filing
2012
- 2012-06-07 SG SG2013085337A patent/SG195035A1/en unknown
- 2012-06-07 RS RS20180086A patent/RS56901B1/sr unknown
- 2012-06-07 MY MYPI2013702375A patent/MY186599A/en unknown
- 2012-06-07 WO PCT/CN2012/076576 patent/WO2012167733A1/en active Application Filing
- 2012-06-07 HU HUE12797167A patent/HUE037934T2/hu unknown
- 2012-06-07 CN CN201280027852.9A patent/CN103596952B/zh active Active
- 2012-06-07 BR BR112013031405-2A patent/BR112013031405B1/pt active IP Right Grant
- 2012-06-07 DK DK12797167.9T patent/DK2718293T3/da active
- 2012-06-07 JP JP2014513893A patent/JP5940148B2/ja active Active
- 2012-06-07 ES ES12797167T patent/ES2657549T3/es active Active
- 2012-06-07 PL PL12797167T patent/PL2718293T3/pl unknown
- 2012-06-07 SI SI201231176T patent/SI2718293T1/en unknown
- 2012-06-07 PT PT127971679T patent/PT2718293T/pt unknown
- 2012-06-07 RU RU2013158996/04A patent/RU2569635C9/ru active
- 2012-06-07 US US14/124,325 patent/US9434726B2/en active Active
- 2012-06-07 NO NO12797167A patent/NO2718293T3/no unknown
- 2012-06-07 LT LTEP12797167.9T patent/LT2718293T/lt unknown
- 2012-06-07 KR KR1020137035164A patent/KR101571720B1/ko active IP Right Grant
- 2012-06-07 AU AU2012266941A patent/AU2012266941B2/en active Active
- 2012-06-07 EP EP12797167.9A patent/EP2718293B1/en active Active
- 2012-06-07 PE PE2013002777A patent/PE20141167A1/es active IP Right Grant
- 2012-06-07 MX MX2013014242A patent/MX355671B/es active IP Right Grant
- 2012-06-07 CA CA2836227A patent/CA2836227C/en active Active
- 2012-06-08 TW TW101120631A patent/TWI494311B/zh active
- 2012-07-06 UA UAA201315617A patent/UA111744C2/uk unknown
2013
- 2013-11-12 IL IL229410A patent/IL229410A/en active IP Right Grant
- 2013-11-27 ZA ZA2013/08947A patent/ZA201308947B/en unknown
- 2013-12-06 CL CL2013003512A patent/CL2013003512A1/es unknown
2014
- 2014-04-01 HK HK14103113.0A patent/HK1190143A1/zh unknown
2015
- 2015-12-28 JP JP2015255844A patent/JP6175484B2/ja active Active
2016
- 2016-07-15 US US15/211,353 patent/US10052330B2/en active Active
2018
- 2018-01-22 CY CY20181100080T patent/CY1119953T1/el unknown
- 2018-01-24 HR HRP20180139TT patent/HRP20180139T1/hr unknown

Also Published As

Publication number	Publication date
US20140121200A1 (en)	2014-05-01
CL2013003512A1 (es)	2014-07-18
KR20140025559A (ko)	2014-03-04
MX355671B (es)	2018-04-26
IL229410A (en)	2017-08-31
BR112013031405A2 (pt)	2016-12-06
DK2718293T3 (da)	2018-01-29
ZA201308947B (en)	2020-02-26
NZ617765A (en)	2016-02-26
KR101571720B1 (ko)	2015-11-25
BR112013031405B1 (pt)	2021-12-21
US20160324864A1 (en)	2016-11-10
JP2014516059A (ja)	2014-07-07
PL2718293T3 (pl)	2018-05-30
SG195035A1 (en)	2013-12-30
HK1190143A1 (zh)	2014-06-27
ES2657549T3 (es)	2018-03-05
CN103596952B (zh)	2016-05-04
EP2718293A1 (en)	2014-04-16
LT2718293T (lt)	2018-02-12
HUE037934T2 (hu)	2018-09-28
AU2012266941A1 (en)	2013-11-28
US9434726B2 (en)	2016-09-06
EP2718293B1 (en)	2017-10-25
CY1119953T1 (el)	2018-12-12
TW201305160A (zh)	2013-02-01
MX2013014242A (es)	2014-04-14
US10052330B2 (en)	2018-08-21
JP5940148B2 (ja)	2016-06-29
RS56901B1 (sr)	2018-05-31
WO2012167733A1 (en)	2012-12-13
CA2836227C (en)	2016-08-16
JP6175484B2 (ja)	2017-08-02
TWI494311B (zh)	2015-08-01
RU2569635C2 (ru)	2015-11-27
SI2718293T1 (en)	2018-04-30
UA111744C2 (uk)	2016-06-10
RU2013158996A (ru)	2015-07-20
CA2836227A1 (en)	2012-12-13
HRP20180139T1 (hr)	2018-05-18
RU2569635C9 (ru)	2016-07-10
CN103596952A (zh)	2014-02-19
AU2012266941B2 (en)	2016-03-31
JP2016106100A (ja)	2016-06-16
PE20141167A1 (es)	2014-09-03
WO2012167423A1 (en)	2012-12-13
PT2718293T (pt)	2018-01-30
IL229410A0 (en)	2014-01-30
MY186599A (en)	2021-07-29
EP2718293A4 (en)	2014-12-03

Publication	Publication Date	Title
BR112013022641A2 (zh)	2017-09-21
AP3853A (zh)	2016-09-30
BR112013031251A2 (zh)	2017-09-12
BR112013024383A2 (zh)	2021-12-07
BR112013023185A2 (zh)	2017-01-03
BR112013022995A2 (zh)	2012-09-13
BR112013017670A2 (zh)	2017-08-15
BR112013023927A2 (zh)	2017-09-12
BR112013024365A2 (zh)	2017-01-03
AP2016009466A0 (zh)	2016-09-30
BR112013031556A2 (zh)	2017-08-29
BR112013026790A2 (zh)	2017-05-02
BR112013024588A2 (zh)	2017-01-03
BR112013032380A2 (zh)	2017-01-03
BR112013032377A2 (zh)	2017-01-03
BR112013032368A2 (zh)	2017-01-03
BR112013018949A2 (zh)	2017-09-12
BR112013021637A2 (zh)	2012-11-01
NO2718293T3 (zh)	2018-03-24
BR112013023266A2 (zh)	2017-09-12
BR112013032392A2 (zh)	2017-01-03
BR112013017878A2 (zh)	2017-08-15
BR112013032394A2 (zh)	2017-01-03
BR112013022499A2 (zh)	2012-09-13
AP3777A (zh)	2016-08-31